APOA1 and leukemia: In light of the interesting observations by Komiya et al. and Yun et al. that low HDL-cholesterol levels are a marker of poorer clinical outcome in patients with lymphocytic leukemia (Komiya et al., 2018; Yun et al., 2021), HDL and its key protein component APOA1 could possibly also serve as therapeutic moieties for the treatment of leukemia.